Press Release

NEW YORK and LONDON, March 1, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today that …

[Read more...] about Akari Therapeutics to Present at Cowen and Company 36th Annual Health Care Conference

NEW YORK and LONDON, February 17, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics to Participate in the 2016 SunTrust Robinson Humphrey Orphan Drug Day

NEW YORK and LONDON, January 29, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today the …

[Read more...] about Akari Therapeutics Receives Approval from the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial

NEW YORK and LONDON, January 27, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today …

[Read more...] about Akari Therapeutics to Participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day

NEW YORK and LONDON, January 5, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced an update …

[Read more...] about Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays